This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abletshauser, C. Articles by Hanefeld, M. Search for Related Content Social Bookmarking                         What's this?

Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus

Novartis Pharma GmbH, Nurnberg, Germany

Patrick Brunel

Novartis Pharma AG, Basel, Switzerland

Klaus-Henning Usadel

Department of Medicine, Johann Wolfgang Goethe University, Frankfurt

Markolf Hanefeld

Zentrum für Klinsiche Studien, GWT der TU Dresden, Germany, hanefeld{at}gwt-tud.de

Aim — The purpose of this study was to compare the effect of nateglinide on two-hour post-meal glucose levels with that of glimepiride in patients with type 2 diabetes mellitus. Methods — Glucose and insulin levels were measured during 14-hour profiles (comprising three meal challenges) and intravenous glucose tolerance tests performed before and after five-weeks of treatment with nateglinide (120 mg, a.c.) or glimepiride (1 mg, o.d.) in a randomised, two-centre, double-blind, crossover study in 26 patients with type 2 diabetes and fasting initial glucose levels < 13.9 mmol/L. Results — Mean two-hour postprandial glucose levels were significantly lower during nateglinide treatment than during glimepiride treatment (9.46 vs. 10.00 mmol/L, respectively; p<0.05). The 14-hour incremental glucose area under the curve was -2.2 mmol•h/L during nateglinide treatment and +6.2 mmol•h/L during glimepiride treatment (p<0.01). Nateglinide improved both the early insulin response during meals and the acute insulin response during intravenous glucose tolerance tests, restoring the biphasic insulin secretion pattern. Both insulin secretagogues improved intravenous glucose tolerance relative to the pre-treatment period, but only nateglinide restored a biphasic insulin profile. Conclusions — By restoring a more physiological post-load insulin response, nateglinide is more effective than glimepiride in controlling postprandial glucose excursions.

Key Words: glimepiride • nateglinide • postprandial hyperglycaemia • type 2 diabetes mellitus.

References

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Eng/J Med 1993;329:977-86.[CrossRef]
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6.[Abstract]
• Bastyr EJ III, Stuart CA, Brodows RG et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000;23:1236-41.[Abstract/Free Full Text]
• Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-5.[Abstract/Free Full Text]
• Hanefeld M., Fischer S., Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996;39:1577-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.[Abstract/Free Full Text]
• Rodriguez BL, Lau N., Burchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu heart program. Diabetes Care 1999;22:1262-5.[Abstract]
• Saydah SH, Miret M., Sung J., Varas C., Gause D., Brancati FL Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001;24:1397-402.[Abstract/Free Full Text]
• Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-8.[Abstract/Free Full Text]
• Rosenstock J., Shen SG, Gatlin MR, Foley JE Combination therapy with nateglinide and a thiazolidinedione improves glycaemic control in type 2 diabetes. Diabetes Care 2002;25:1529-33.[Abstract/Free Full Text]
• Horton ES, Clinkingbeard C., Gatlin M., Foley J., Mallows S., Shen S. Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.[Abstract/Free Full Text]
• Rosenstock J., Samols E., Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996;19:1194-9.[Abstract]
• Niemi M., Neuvonen PJ, Kivisto KT Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;70:439-45.[Web of Science][Medline] [Order article via Infotrieve]
• Schade DS, Jovanovic L., Schneider J. A placebo-controlled, randomised study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-41.[Abstract]
• Karara AH, Dunning BE, McLeod JF The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999;39:172-9.[Abstract]
• Mitrakou A., Kelley D., Mokan M. et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.[Abstract]
• Bruttomesso D., Pianta A., Mari A. et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.[Abstract]
• Hanefeld M., Haffner SM, Menschikowski M. et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract 2002;55:221-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Monnier L., Colette C., Rabasa-Lhoret R. et al. Morning hyperglycaemic excursions: a constant failure in the metabolic control of non-insulinusing patients with type 2 diabetes. Diabetes Care 2002;25:737-41.[Abstract/Free Full Text]
• Podolsky D. Gasping for life. U.S. News and World Report [January 13], 61-65. 1997. Ref Type: Magazine Article.
• Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-9.[Abstract/Free Full Text]
• Gomis R., Novials A., Coves MJ, Casamitjana R., Malaisse WJ Suppression by insulin treatment of glucose-induced inhibition of insulin release in non-insulin-dependent diabetics. Diabetes Res Clin Pract 1989;6:191-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus. Diabet Med 2000;17:225-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kahn SE, Montgomery B., Howell W. et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824-9.[Abstract/Free Full Text]
• Groop L., Luzi L., Melander A. et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987;36:1320-8.[Abstract]
• Holstein A., Plaschke A., Egberts EH Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28:426-9.[Web of Science][Medline] [Order article via Infotrieve]
• Ligueros-Saylan M., Khalilieh S., Lee J. et al. Nateglinide has a low hypoglycaemic potential in a missed-meal situation. Diabetologia 2000;43 (suppl. 1):A187.
• Walter YH, Brookman L., Ma P., Grich JE, McLeod JF Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide. Diabetes 2000;49(suppl 1):A128-A129.
• Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract Suppl 2002;129:45-50.[Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 2, 93-99 (2005)
DOI: 10.1177/14746514050050020701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abletshauser, C. Articles by Hanefeld, M. Search for Related Content Social Bookmarking                         What's this?